Multicentric Phase II Trial of Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2016
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms GETUG P07; OLIGOPELVIS
- 10 Jun 2017 Biomarkers information updated
- 30 Aug 2016 Planned End Date changed from 1 Sep 2026 to 1 Jul 2026.
- 30 Aug 2016 Status changed from recruiting to active, no longer recruiting.